University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Mitomycin-C Application in Laryngotracheal Stenosis

Not Applicable

Terminated

Conditions: Laryngeal Stenosis
Subglottic Stenosis
Tracheal Stenosis

Interventions: Drug: Mitomycin -C
Other: Saline application

First Posted Date: 2012-02-01

Last Posted Date: 2019-05-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 15

Registration Number: NCT01523275

Locations: 🇺🇸
UCSF - Voice and Swallowing Clinic, San Francisco, California, United States

L-carnitine to Treat Fatigue Associated With Crohn's Disease

Not Applicable

Withdrawn

Conditions: Crohn's Disease
Fatigue

Interventions: Other: Placebo
Drug: L-carnitine

First Posted Date: 2012-02-01

Last Posted Date: 2014-01-17

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01523106

Locations: 🇺🇸
UCSF Medical Center, Mt. Zion Medical Center, San Francisco, California, United States

Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection

Completed

Conditions: Atherosclerosis

First Posted Date: 2012-01-26

Last Posted Date: 2021-11-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 579

Registration Number: NCT01519141

Locations: 🇺🇸
University of California San Francisco, San Francisco General Hospital, San Francisco, California, United States

Anakinra as a Treatment for Hydradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Drug: anakinra

First Posted Date: 2012-01-25

Last Posted Date: 2014-08-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 6

Registration Number: NCT01516749

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Phase 1

Completed

Conditions: BRAF Mutant Metastatic Melanoma

Interventions: Drug: BKM120 Combined with Vemurafenib (PLX4032)

First Posted Date: 2012-01-19

Last Posted Date: 2020-08-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT01512251

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Ustekinumab

First Posted Date: 2012-01-18

Last Posted Date: 2016-02-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 36

Registration Number: NCT01511315

Locations: 🇺🇸
UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States

Determination of the Duration of Action of a Lidocaine and a Bupivacaine Digital Nerve Block in Human Volunteers

Phase 4

Completed

Conditions: Onset and Duration of a Digital Nerve Block

Interventions: Drug: Bupivacaine Digital Block
Drug: Lidocaine Digital Nerve Block

First Posted Date: 2012-01-12

Last Posted Date: 2020-01-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 12

Registration Number: NCT01508832

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Characterization of Adult Subjects for Asthmatic Research Studies

Suspended

Conditions: Asthma

First Posted Date: 2012-01-11

Last Posted Date: 2023-02-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 259

Registration Number: NCT01508078

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

Not Applicable

Completed

Conditions: Peripheral Arterial Disease

Interventions: Procedure: Administration of dexamethasone to SFA/popliteal adventitia

First Posted Date: 2012-01-11

Last Posted Date: 2018-01-08

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 22

Registration Number: NCT01507558

Locations: 🇺🇸
University of California, San Francisco Medical Center, San Francisco, California, United States
🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States

Drug-Drug Interaction Study With Pravastatin and Cyclosporine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pravastatin alone
Drug: Pravastatin and Cyclosporine

First Posted Date: 2011-12-22

Last Posted Date: 2015-01-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 21

Registration Number: NCT01497483

Locations: 🇺🇸
San Francisco General Hosptail, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy